Press Releases

Bayer has entered into an exclusive global license agreement with Systems Oncology, LLC, for ERSO™, a compound in pre-clinical development for metastatic Estrogen Receptor (ER) positive, breast cancer. ERSO is a small molecule activator of the Unfolded Protein Response (UPR) in ER-positive breast cancer cells. ERSO’s mechanism of action is a therapeutic approach being investigated in women with metastatic ER-positive breast cancer, an area where new therapies are urgently required

Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced a collaboration with Kentucky Organ Donor Affiliates (KODA). KODA is an independent, non-profit organ and tissue procurement organization that facilitates deceased donor transplants throughout Kentucky, southern Indiana and western West Virginia. The collaboration will advance precl

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced that the company has entered into a clinical collaboration and supply agreement with Janssen Biotech, Inc. (Janssen) to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody targeting B-cell maturation antigen

Takeda Pharmaceutical Company Limited is the first non-adaptation of autologous stem cell transplantation Results of Phase 3 TOURMALINE-MM2 study evaluating lenalidomide + dexamethasone plus ninlaro (ixazomib) combination therapy with lenalidomide + dexamethasone plus placebo in patients with multiple myeloma did. The data will be presented at a virtual meeting of the Society of Hematology and Oncology (SOHO) on Wednesday, September 9, 2020 at 6:15 pm CST. In this study, the additio

Bruker Corporation announced the acquisition of Canopy Biosciences, LLC, a leader in high multiplex biomarker imaging for immunology, immuno-oncology and cell therapy. This acquisition enhances Bruker’s offering in targeted multi-omics and fluorescence-based imaging techniques. Bruker’s global reach, complementary technologies and applications knowledge will help build on Canopy’s success to date. Financial details of the transaction were not disclosed. “We a

CMAB Biopharma (Suzhou) Inc. ("CMAB"), and Laekna Therapeutics Shanghai Co., Ltd. ("Laekna Therapeutics"), announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clinical trial and future commercialization. According to the agreement, CMAB will provide a full spectrum of CMC services based on the recognized global quality standards for Laekna Therapeutics' anti-PD-L1 antibody (LAE0

Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. and Galmed Pharmaceuticals Ltd. announces that they have entered into a research agreement aiming at combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of non-alcoholic steatohepatitis (NASH). The financial details of this transaction are not disclosed. ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist which recently received IND approval from China&#

MilliporeSigma announced a $65 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin. This investment will allow large-scale manufacturing of increasingly potent compounds that have the potential to treat cancer. Completion is expected by mid-2022 and should add approximately 50 full-time jobs starting in 2021. "ADCs have posted incredible growth over the last decade and regulatory agencies' approval in recent

Bayer, a global leader in women’s healthcare, today announced that, further to its press release on August 11, 2020, Bayer completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare. “We are pleased to receive antitrust clearance and to officially close on the KaNDY Therapeutics Ltd. acquisition,” said Dr. Sebastian Guth, Bayer’s President of Pharmaceuticals, Americas Regio

Avidity Biosciences, Inc., a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), announced it entered into a collaboration supporting END-DM1, a natural history study to advance the understanding of disease progression in patients with myotonic dystrophy type 1 (DM1). END-DM1 (Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1) is a non-interventional study designed and run